Overview

A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation

Status:
Completed

Trial end date:
2012-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the effect and safety of NKTR-118 treatment of opioid-induced constipation in patients with non-cancer-related pain over a 6-month period.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Analgesics, Opioid
Naloxegol